[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse ERO1A

Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Peripheral membrane protein Lumenal side Note=The association with ERP44 is essential for its retention in the endoplasmic reticulum.
Domain PF04137 Endoplasmic Reticulum Oxidoreductin 1 (ERO1)
Function

Oxidoreductase involved in disulfide bond formation in the endoplasmic reticulum. Efficiently reoxidizes P4HB/PDI, the enzyme catalyzing protein disulfide formation, in order to allow P4HB to sustain additional rounds of disulfide formation. Following P4HB reoxidation, passes its electrons to molecular oxygen via FAD, leading to the production of reactive oxygen species (ROS) in the cell. Required for the proper folding of immunoglobulins. Involved in the release of the unfolded cholera toxin from reduced P4HB/PDI in case of infection by V.cholerae, thereby playing a role in retrotranslocation of the toxin. Plays an important role in ER stress-induced, CHOP-dependent apoptosis by activating the inositol 1,4,5-trisphosphate receptor IP3R1.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001666 response to hypoxia
GO:0006457 protein folding
GO:0006458 'de novo' protein folding
GO:0006575 cellular modified amino acid metabolic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006979 response to oxidative stress
GO:0006986 response to unfolded protein
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007568 aging
GO:0009266 response to temperature stimulus
GO:0010260 animal organ senescence
GO:0019471 4-hydroxyproline metabolic process
GO:0022417 protein maturation by protein folding
GO:0030198 extracellular matrix organization
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0034620 cellular response to unfolded protein
GO:0034975 protein folding in endoplasmic reticulum
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0043062 extracellular structure organization
GO:0045444 fat cell differentiation
GO:0045454 cell redox homeostasis
GO:0050873 brown fat cell differentiation
GO:0051084 'de novo' posttranslational protein folding
GO:0051085 chaperone mediated protein folding requiring cofactor
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051604 protein maturation
GO:0055074 calcium ion homeostasis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0061077 chaperone-mediated protein folding
GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress
GO:0070482 response to oxygen levels
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097553 calcium ion transmembrane import into cytosol
GO:1901605 alpha-amino acid metabolic process
GO:1902656 calcium ion import into cytosol
GO:2000021 regulation of ion homeostasis
Molecular Function GO:0003756 protein disulfide isomerase activity
GO:0015035 protein disulfide oxidoreductase activity
GO:0015036 disulfide oxidoreductase activity
GO:0016667 oxidoreductase activity, acting on a sulfur group of donors
GO:0016671 oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor
GO:0016853 isomerase activity
GO:0016860 intramolecular oxidoreductase activity
GO:0016864 intramolecular oxidoreductase activity, transposing S-S bonds
Cellular Component GO:0005788 endoplasmic reticulum lumen
GO:0030425 dendrite
> KEGG and Reactome Pathway
 
KEGG hsa04141 Protein processing in endoplasmic reticulum
Reactome R-HSA-2262752: Cellular responses to stress
R-HSA-3299685: Detoxification of Reactive Oxygen Species
R-HSA-264876: Insulin processing
R-HSA-392499: Metabolism of proteins
R-HSA-2980736: Peptide hormone metabolism
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ERO1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ERO1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.44; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ERO1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 5901
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4701
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1090.945
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7350.745
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0260.832
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ERO1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ERO1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ERO1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ERO1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ERO1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ERO1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ERO1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolERO1A
Nameendoplasmic reticulum oxidoreductase alpha
Aliases ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location14q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ERO1A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.